Safety of the concurrent treatment of dogs with Bravecto™ (fluralaner) and Scalibor™ protectorband (deltamethrin)

Walther, Feli M; Fisara, Petr; Allan, Mark J; Roepke, Rainer K. A.; Nuernberger, Martin C

doi:10.1186/1756-3305-7-105

Cited by 18 publications

(10 citation statements)

References 4 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with previous data showing no evidence for interactions of Bravecto™ with other routinely used veterinary medicinal products [ 3 , 7 ].…”

Section: Resultssupporting

confidence: 93%

Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime - praziquantel

Walther¹,

Fisara²,

Allan³

et al. 2014

Parasites Vectors

Self Cite

View full text Add to dashboard Cite

BackgroundFluralaner (Bravecto™; Merck/MSD Animal Health) is a novel systemic ectoparasiticide for dogs providing long-acting flea and tick control after a single oral dose. Milbemycin oxime and praziquantel are routinely used to control Dirofilaria immitis and intestinal worm infections in dogs. The safety of concurrent use of fluralaner and a commercially available milbemycin oxime plus praziquantel combination tablet, in particular with regard to gastrointestinal symptoms, was investigated using oral doses at or above the maximum recommended rates.FindingsSome minor and transient clinical findings were observed during the study period; however, none of these was considered to be related to concurrent treatment with fluralaner and milbemycin oxime plus praziquantel, or to the use of either product alone.ConclusionsConcurrent treatment with fluralaner, milbemycin oxime and praziquantel is well tolerated in dogs.

show abstract

“…These results are consistent with previous data showing no evidence for interactions of Bravecto™ with other routinely used veterinary medicinal products [ 3 , 7 ].…”

Section: Resultssupporting

confidence: 93%

Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime - praziquantel

Walther¹,

Fisara²,

Allan³

et al. 2014

Parasites Vectors

Self Cite

View full text Add to dashboard Cite

show abstract

“…In conclusion, fluralaner treatment of dogs represents a promising method for reducing the pool of infected vectors in endemic settings of zoonotic VL. Furthermore, the use of fluralaner in combination with preventive topical pyrethroid treatments, provided that this is not contraindicated for a dog's safety (Walther et al ., ), could provide benefits for dogs in high‐risk areas.…”

Section: Mean ± Sd Proportions Of Surviving Blood‐fed Phlebotomus Permentioning

confidence: 99%

A single oral dose of fluralaner (Bravecto®) in dogs rapidly kills 100% of blood‐fed Phlebotomus perniciosus, a main visceral leishmaniasis vector, for at least 1 month after treatment

Bongiorno

Meyer²,

Evans³

et al. 2019

Medical Vet Entomology

View full text Add to dashboard Cite

Dogs are the reservoir host of zoonotic visceral leishmaniasis (VL) caused by Leishmania infantum (Kinetoplastida: Trypanosomatidae). Both subclinically-infected and sick animals can be infectious to competent phlebotomine vectors. The degree and duration of insecticidal efficacy of an oral dose of fluralaner (Bravecto ® ; Merck Animal Health) was determined in dogs exposed to bites of Phlebotomus perniciosus (Diptera: Psychodidae), a main Mediterranean vector of VL. Twelve dogs allocated to two groups of six animals each were included in a parallel-group designed, negative-controlled, randomized, blinded, single-centre efficacy study. Group 2 was treated with fluralaner on day 0, and sand-fly exposure of both groups was performed on days 1, 28 and 84. Viability of blood-fed females was assessed up to 96 h after exposure and efficacy was measured as the survival rate of specimens fed on Group 2 versus those fed on Group 1. A mortality of 100% was recorded at 24 h in females fed on Group 2 at both days 1 and 28. Significant insecticidal efficacy was still observed on day 84, with > 50% mortality recorded by 48 h post blood meal in Group 2. Fluralaner treatment of dogs represents a promising and affordable method for reducing the pool of infected vectors in endemic settings of zoonotic VL.

show abstract

“…Safety studies regarding the concurrent application of systemic insecticides and topical repellent products should be undertaken. For example, fluralaner and deltamethrin collars are well-tolerated (60). Using insecticides indoors and/or around the houses/kennels where dogs live could be of benefit, although the effect may not last long (46).…”

Section: Prevention Prevention Of Infection By Repellentsmentioning

confidence: 99%

Aktuelle Kenntnisse zu Therapie und Prävention der kaninen Leishmaniose

Apostolopoulos¹,

Mitropoulou²,

Thom³

et al. 2018

Tierarztl Prax Ausg K

View full text Add to dashboard Cite

ZusammenfassungDie kanine Leishmaniose ist eine Infektionskrankheit, die zunehmend an Bedeutung gewinnt, da auch in Deutschland der Hauptvektor der Leishmaniose vorkommt und Einzelfälle autochthoner Infektionen beschrieben sind. Der Artikel fasst aktuelle Informationen über Therapie und Prävention der Leishmaniose zusammen. Kürzlich wurden bei Hunden, die unter Allopurinoltherapie ein Rezidiv der Erkrankung erlitten, Allopurinol-resistente Leishmania-infantum-Stämme gefunden. Daher werden alternative Langzeittherapien erforderlich. Auch die Ergebnisse aus Langzeitstudien zur Effizienz von Miltefosin im Vergleich zu Megluminantimonat können die Wahl des leishmaniziden Therapeutikums beeinflussen. Eine Vielzahl verschiedener Repellenzien steht zur Übertragungsprophylaxe zur Verfügung. In Europa sind zwei Impfstoffe für Hunde zugelassen, um das Risiko einer aktiven Infektion und den Schweregrad der klinischen Erkrankung zu reduzieren.

show abstract

Safety of the concurrent treatment of dogs with Bravecto™ (fluralaner) and Scalibor™ protectorband (deltamethrin)

Cited by 18 publications

References 4 publications

Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime - praziquantel

Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime - praziquantel

A single oral dose of fluralaner (Bravecto®) in dogs rapidly kills 100% of blood‐fed Phlebotomus perniciosus, a main visceral leishmaniasis vector, for at least 1 month after treatment

Aktuelle Kenntnisse zu Therapie und Prävention der kaninen Leishmaniose

Contact Info

Product

Resources

About